Sanofi Expands $35 Monthly Insulin Program to All Americans Regardless of Insurance Status
核心洞察
Sanofi will expand its Insulins Valyou Savings Program to offer all its insulin products for $35 per month to every American with a valid prescription starting January 1, 2026.
The program expansion includes patients with commercial insurance and Medicare beneficiaries, removing previous restrictions that limited the program to uninsured patients.
The initiative addresses diabetes care for approximately 38.4 million Americans diagnosed with diabetes, representing 11.6% of the U.S. population according to CDC data.
Sanofi announced a significant expansion of its insulin affordability program, making all of its insulin products available for $35 per month to every American with a valid prescription, regardless of insurance status. The expanded Insulins Valyou Savings Program will take effect January 1, 2026, and represents a major shift in pharmaceutical pricing strategy for diabetes medications.
Program Expansion Details
The pharmaceutical company originally launched the Valyou Savings Program in 2022, initially lowering the cost of 30-day insulin packages from $99 to $35 for diabetic patients without insurance. The new expansion removes insurance status restrictions, making the program available to all Americans, including those with commercial insurance and Medicare beneficiaries.
"Our announcement builds on an idea first championed by President Trump to lower costs for American patients at the pharmacy counter. At Sanofi, we share his objective and believe that no one should struggle to afford their insulin and we are proud to take this next step as we play our part to keep America healthy," said Adam Gluck, Head of US Corporate Affairs, Sanofi.
Under the expanded program, patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35. The program will work at most pharmacies across the United States, including independent and rural pharmacies, without creating complex hurdles for patients.
Addressing Critical Healthcare Needs
The program expansion targets a substantial patient population, with approximately 38.4 million Americans, representing 11.6% of the population, diagnosed with diabetes according to the CDC. The initiative aims to address financial barriers that can lead to medication rationing or dose skipping, which can have serious health consequences.
"Diabetes management requires consistent access to medication, and financial barriers can lead to rationing or skipping doses, which can have serious health consequences," said Olivier Bogillot, Head of General Medicines, North America, Sanofi. "This program expansion emphasizes our continued support for America's diabetes community."
Implementation and Access
Sanofi's expanded program ensures that no American will need to pay more than $35 per month for their Sanofi insulins. The company emphasizes that the program will be implemented nationwide and will cover all Sanofi insulin products.
Patients can enroll in the expanded Insulins Valyou Savings Program beginning January 1, 2026, through Sanofi Patient Connection or by calling 1-888-847-4877. The program builds on Sanofi's longstanding commitment to access and affordability in diabetes care.
"By expanding our Insulins Valyou Savings Program, we're taking concrete action to address a critical healthcare issue for millions of Americans living with diabetes," Gluck stated. "We will continue to work with policymakers and stakeholders across the healthcare system on additional sustainable, long-term solutions to improve access to medicines."